

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

AQUESTIVE THERAPEUTICS, INC.,

Petitioner,

v.

NEURELIS, INC.,

Patent Owner.

---

Case IPR2019-00451

Patent 9,763,876

---

**PATENT OWNER UPDATED EXHIBIT LIST**

| <b>Exhibit No.</b> | <b>Description</b>  |
|--------------------|---|
| 2001               | Epilepsy Fast Facts, CDC (Center for Disease Control and Preventions), CDC 24/7: Saving Lives, Protection People™, Apr. 9, 2019, pp. 1-2.   |
| 2002               | Grant Fast Track – Dept. of Health and Human Services re: IND 112621; NRL-1 (diazepam intranasal solution), Dec. 27, 2016, pp 1-2.  |
| 2003               | Howard LeWine, M.D., “Quick Injection Helps Stop Epileptic Seizures,” Harvard Health Blog, Feb. 23, 2012; p. 1  |
| 2004               | “Managing Epilepsy Well Network and Selected Self-Management Programs; Putting Collective Wisdom to Work for People with Epilepsy,” Prevention Research Centers (PRC), CDC , Nov. 2016, pp.1-17 |
| 2005               | K.M. Fiest, et al., “Prevalence and Incidence of Epilepsy, A Systematic Review and Meta-Analysis of International Studies,” NEUROLOGY 88, Jan. 17, 2017, pp.296-303                             |
| 2006               | SIGMA Chemical Company Catalog (1988)   |
| 2007               | E. Bechgaard et al., “Solubilization of Various Benzodiazepines for Intranasal Administration, A Pilot Study,” Pharmaceutical Development and Technology 2:293-296 (1997)                       |
| 2008               | A. Hussain et al. “Nasal Absorption of Propranolol in Humans,” Journal of Pharmaceutical Sciences 69:1240 (1980)  |
| 2009               | S. Lau and J. Slattery, “Absorption of Diazepam and Lorazepam Following Intranasal Administration,” International Journal of Pharmaceutics, 54:171-174 (1989)                                   |
| 2010               | M. Schols-Hendriks et al., “Absorption of Clonazepam After Intranasal and Buccal Administration,” British Journal of Clinical Pharmacology 39:449-451 (1995)                                    |
| 2011               | Dr. Nicholas Peppas Deposition Transcript, October 24, 2019.  |

|      |  |
|------|--|
| 2012 | Declaration of Dr. Sveinbjorn Gizurarson, Ph.D.  |
| 2013 | J. Riss et al., “Benzodiazepines in Epilepsy: Pharmacology and Pharmacokinetics,” <i>Acta Neurologica Scandinavica</i> 118:69-86 (2008)  |
| 2014 | D. Wermeling, U.S. Patent No. 6,610,271, issued August 26, 2003  |
| 2015 | C. Cole et al., “Community Survey of Carer’s: Individual Epilepsy Guidelines (IEG) for Rescue Medication,” <i>Seizure</i> 18:220-224 (2009)  |
| 2016 | D. Terry et al., “Acceptance of the Use of Diazepam Rectal Gel in School and Day Care Settings,” <i>Journal of Child Neurology</i> 22:1135-1138 (2007)   |
| 2017 | Diastat® Label (2005)  |
| 2018 | “UCB announces NAYZILAM® (midazolam) nasal spray now approved by FDA to treat intermittent, stereotypic episodes of frequent seizure activity in people living with epilepsy in the U.S.,” UCB Press Release, <a href="https://www.biospace.com/article/releases/ucb-announces-nayzilam-midazolam-nasal-spray-now-approved-by-fda-to-treat-intermittent-stereotypic-episodes-of-frequent-seizure-activity-in-people-living-with-epilepsy-in-the-u-s/">https://www.biospace.com/article/releases/ucb-announces-nayzilam-midazolam-nasal-spray-now-approved-by-fda-to-treat-intermittent-stereotypic-episodes-of-frequent-seizure-activity-in-people-living-with-epilepsy-in-the-u-s/</a> (2019) (Accessed October 31, 2019) |
| 2019 | J. French and T. Pedley, “Initial Management of Epilepsy,” <i>New England Journal of Medicine</i> 359:166-176 (2008)   |
| 2020 | G. Corbo et al. “Measurement of Nasal Mucociliary Clearance,” <i>Archives of Disease in Childhood</i> 64:546-550 (1989)  |
| 2021 | “How does the nose work? The nasal mucosa,” <a href="https://www.fitonasal2act.com/how-does-the-nose-work/the-nasal-mucosa/">https://www.fitonasal2act.com/how-does-the-nose-work/the-nasal-mucosa/</a> (Accessed November 5, 2019)  |
| 2022 | N. Mygind, “Nasal Allergy,” 9 (Blackwell Scientific Publications, 1979)  |
| 2023 | “Neurelis Files New Drug Application With The FDA For VALTOCO™ (Diazepam Nasal Spray), An Investigational Treatment For Pediatric, Adolescent And Adult Epilepsy Patients,”  |

|      |  |
|------|--|
|      | <a href="https://www.neurelis.com/neurelis-news/neurelis-files-new-drug-application-fda-valtocoTM-nasal-spray-investigational-treatment-pediatric">https://www.neurelis.com/neurelis-news/neurelis-files-new-drug-application-fda-valtocoTM-nasal-spray-investigational-treatment-pediatric</a> (2018) (Accessed November 1, 2019) |
| 2024 | “Neurelis Receives FDA Orphan Drug Designation for NRL-1 in the Treatment of Acute Repetitive Seizures,”<br><a href="https://www.neurelis.com/neurelis-news/fda-orphan-drug-designation">https://www.neurelis.com/neurelis-news/fda-orphan-drug-designation</a> (2015) (Accessed November 1, 2019)                                 |
| 2025 | Affidavit of Robert Cleary (Dated November 21, 2019) [SERVED BUT NOT FILED]  |
| 2026 | Affidavit of Ronald Figueroa (Dated November 21, 2019) [SERVED BUT NOT FILED]  |
| 2027 | Transcript of Telephone Conference on Feb. 11, 2020  |
| 2028 | “Intranasal Technology, Inc. Licenses Aegis Therapeutics' Intravital Drug Delivery Technology” (Business Wire) (April 13, 2005)  |
| 2029 | Handbook of Pharmaceutical Excipients (Pharmaceutical Press and American Pharmacists Association, Publishers) (Fifth Edition, 2006)  |
| 2030 | J. Wyse, U.S. Patent No. 9,192,570 issued November 24, 2015  |
| 2031 | Daniel P. Wermeling Deposition Transcript, February 26, 2020   |
| 2032 | “ITI Announces Formation of Scientific Advisory Board Led by the Dean of the University of Iowa’s College of Pharmacy,” ITI Press Release (2006) [SERVED BUT NOT FILED]  |
| 2033 | Declaration of Dr. Sveinbjorn Gizurarson, Ph.D. [SERVED BUT NOT FILED]   |
| 2034 | Declaration of Edward Maggio, Ph.D. [SERVED BUT NOT FILED]   |

Dated: March 31, 2020

/Lorelei P. Westin /  
Lorelei P. Westin, Ph.D., Esq.  
Reg. No. 52,353

## CERTIFICATE OF SERVICE

I certify that this paper and exhibits 2032-2034 were served electronically on March 31, 2020, to the following addresses:

|                       |  |
|-----------------------|--|
| Daniel A. Scola, Jr.  | <a href="mailto:dscola@hbiplaw.com">dscola@hbiplaw.com</a>           |
| Michael I. Chakansky  | <a href="mailto:mchakansky@hbiplaw.com">mchakansky@hbiplaw.com</a>   |
| James F. Harrington   | <a href="mailto:jharrington@hbiplaw.com">jharrington@hbiplaw.com</a> |
| Matthew J. Solow      | <a href="mailto:msolow@hbiplaw.com">msolow@hbiplaw.com</a>           |
| John T. Gallagher     | <a href="mailto:jgallagher@hbiplaw.com">jgallagher@hbiplaw.com</a>   |
| Hoffmann & Baron, LLP | <a href="mailto:876IPR@hbiplaw.com">876IPR@hbiplaw.com</a>           |

Dated: March 31, 2020

Michelle Lee /  
Michelle Lee